NR2E3 and Abnormal retinal morphology: The results of this pharmacology study are translational to dosage selection of NR2E3 as a therapeutic agent, longitudinal therapeutic effectiveness, and treatment effectiveness in early and intermediate stage NR2E3-associated retinal disease in clinical trials.